Pierre Fabre Group
The Cell Therapy Lead at Pierre Fabre is the Belgium-based local lead for the T‑cell immunotherapy Ebvallo (tabelecleucel), acting as the primary Belgian contact and liaison with the French headquarters. The role sits within the Oncology business unit and supports the local implementation and strategic alignment of the therapy across Belgian hospitals and treatment centers. The position is based in Belgium and follows a hybrid work model.
Founded in 1962 by Mr. Pierre Fabre, Pierre Fabre is an international French pharmaceutical and dermo-cosmetic group owned by a public benefit foundation and its employees.
Naos appoints Frédéric Ennabli, former Pierre Fabre executive, as board chairman
Sep 29, 2025
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
Oct 10, 2022
Pierre Fabre Has Acquired Dermocosmetics Brand Même
May 9, 2023
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pierre Fabre Group.
Pierre Fabre Group didn’t post a salary, so this is our estimate from similar listings.
Eric Ducournau Named Chief Executive Officer of the Pierre Fabre Group
May 31, 2018
Cell Therapy Account Manager
Gilead Sciences
Process Engineer, Cell Therapy Process Development
AstraZeneca
Cell Therapy Account Manager
Gilead Sciences
Scientist, Cell Therapy Bioscience
AstraZeneca
Senior Medical Science Liaison – Cell Therapy (Midwestern US)
AstraZeneca
National Head of Cell Therapy Account Management Team Germany (m/f/d)
Gilead Sciences